36 related articles for article (PubMed ID: 32918130)
1. Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials.
Ran T; Chen J; She Q; Mu Y; Zhang M; Mao M; Zuo Z; Li J
PLoS One; 2024; 19(5):e0303208. PubMed ID: 38781221
[TBL] [Abstract][Full Text] [Related]
2. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729).
Wong ML; Gao J; Thanarajasingam G; Sloan JA; Dueck AC; Novotny PJ; Jatoi A; Hurria A; Walter LC; Miaskowski C; Cohen HJ; Wood WA; Feliciano JL; Stinchcombe TE; Wang X
Oncologist; 2021 Mar; 26(3):e435-e444. PubMed ID: 32951293
[TBL] [Abstract][Full Text] [Related]
3. Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.
Coltelli L; Finale C; Musettini G; Fontana A; Barletta MT; Lucarini AR; Fabiani I; Scalese M; Bocci G; Masini LC; Soria G; Cupini S; Arrighi G; Barbara C; De Maio E; Salvadori B; Marini A; Pellino A; Stasi I; Emdin M; Giaconi S; Marcucci L; Allegrini G
Clin Exp Med; 2023 Dec; 23(8):5113-5120. PubMed ID: 37634231
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment.
Adesoye T; Liao KP; Peterson S; Li L; Zorzi D; Holmes HM; Chavez-MacGregor M; Giordano SH
Cancer Med; 2023 Sep; 12(17):17740-17752. PubMed ID: 37551136
[TBL] [Abstract][Full Text] [Related]
5. The effects of low-dose anthracycline-based chemotherapy on the levels of serum NT-proBNP level and left ventricular systolic and diastolic dysfunctions: A prospective observational study.
Mohammadi F; Bigdelu L; Allahyari A; Morovatdar N; Rahimi VB
Health Sci Rep; 2022 Sep; 5(5):e841. PubMed ID: 36189408
[TBL] [Abstract][Full Text] [Related]
6. GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients.
Zeng J; Wu H; Liu D; Li L; Li J; Wang Q; Ye M; Huang Q; Yu Z; Zhang J
World J Surg Oncol; 2022 Jun; 20(1):212. PubMed ID: 35729577
[TBL] [Abstract][Full Text] [Related]
7. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
Nyrop KA; Deal AM; Shachar SS; Basch E; Reeve BB; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Reeder-Hayes KE; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Oncologist; 2019 Jun; 24(6):762-771. PubMed ID: 30552158
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
10. Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women.
Delgado-Ramos GM; Nasir SS; Wang J; Schwartzberg LS
Breast Cancer Res Treat; 2020 Jul; 182(2):247-258. PubMed ID: 32447595
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
13. Acute toxicity and tolerability of anthracycline-based chemotherapy regimens in older versus younger patients with breast cancer: real-world data.
Monteiro AR; Garcia AR; Póvoa S; Soares RF; Macedo F; Pereira TC; Domingues I; Pazos I; Sousa G
Support Care Cancer; 2021 May; 29(5):2347-2353. PubMed ID: 32918130
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
